B-Cell Maturation Antigen (BCMA): hot target for emerging treatment modalities
![](/report_cover/2374/b-cell-maturation-antigen-bcma-hot-target-4-emerging-treatment-modalities_en.gif)
B-Cell Maturation Antigen (BCMA): hot target for emerging treatment modalities
The highly restricted expression of B-cell maturation antigen (BCMA) to plasma cells and its role in the survival and growth for multiple myeloma cells makes BCMA a good potential target for enhanced immunotherapeutic strategies. This report describes and analyzes the
The highly restricted expression of B-cell maturation antigen (BCMA) to plasma cells and its role in the survival and growth for multiple myeloma cells makes BCMA a good potential target for enhanced immunotherapeutic strategies. This report describes and analyzes the
- Scientific rationale for BCMA-targeted therapies;
- Preclinical proof-of-concept of BCMA blockade;
- Clinical experience with BCMA-targeted therapies;
- The competitive landscape of BCMA-targeted treatment modalities;
- Profiles of anti-BCMA CAR T-cells, antibody-drug conjugate and T-cell redirecting bispecific antibodies:
- Profiles of companies involved in develompent of anti-BCMA therapy candidates.
1 Target Background
2 Target Antigen Expression Profile
3 Preclinical Proof-of-Concept
4 Clinical Indications & Treatment Options
5 Clinical Experience with BCMA-Targeted Treatment Modalities
6 Treatment Modalities & Competitive Landscape
7 Drug & Cell Therapy Candidate Profiles
7.1 CAR T-Cells
7.2 Antibody-Drug Conjugate (ADC)
7.3 T-Cell Redirecting Antibodies
8 Company Profiles
9 References
2 Target Antigen Expression Profile
3 Preclinical Proof-of-Concept
4 Clinical Indications & Treatment Options
5 Clinical Experience with BCMA-Targeted Treatment Modalities
6 Treatment Modalities & Competitive Landscape
7 Drug & Cell Therapy Candidate Profiles
7.1 CAR T-Cells
7.2 Antibody-Drug Conjugate (ADC)
7.3 T-Cell Redirecting Antibodies
8 Company Profiles
9 References